Bayer acquires rights to Bioton's insulin SciLin

Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton's Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acquires the exclusive right to market and distribute insulin produced by Bioton under the trade name of SciLin in China. The contract and payment guarantee the exclusive commercial delivery of this recombinant insulin to Bayer in China with a secured supply of the product for the next 15 years. 


Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying